Stocks · News reference
Dyadic International Inks New Development, Commercial License Agreement With European Biotechnology Firm For Additional Precision Fermented Dairy Proteins
Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — DYADIC INTERNATIONAL INC (DYAI)
Filed: 2026-09-25 AccNo: 0001493152-26-044398 Size: 227 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Dyadic International shares are trading lower after the company announced a $2.9 million offering and concurrent private placement.
Dyadic International Announces Definitive Agreements For $2.9M Registered Direct Offering And Concurrent Private Placement Of Warrants With Institutional Investor
Dyadic International, Inc. (NASDAQ:DYAI) (the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition,